| scholarly article | Q13442814 |
| P356 | DOI | 10.1161/01.CIR.101.8.841 |
| P698 | PubMed publication ID | 10694520 |
| P50 | author | Philippe Gabriel Steg | Q16027739 |
| Ziad Mallat | Q45827826 | ||
| P2093 | author name string | Tedgui A | |
| Freyssinet JM | |||
| Benamer H | |||
| Benessiano J | |||
| Hugel B | |||
| P433 | issue | 8 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | patient | Q181600 |
| P304 | page(s) | 841-843 | |
| P577 | publication date | 2000-02-01 | |
| P1433 | published in | Circulation | Q578091 |
| P1476 | title | Elevated levels of shed membrane microparticles with procoagulant potential in the peripheral circulating blood of patients with acute coronary syndromes. | |
| P478 | volume | 101 |
| Q37444651 | 4-Hydroxy-2-nonenal enhances tissue factor activity in human monocytic cells via p38 mitogen-activated protein kinase activation-dependent phosphatidylserine exposure |
| Q42418327 | A novel broadband impedance method for detection of cell-derived microparticles |
| Q38321079 | A novel method for overexpression of peroxisome proliferator-activated receptor-γ in megakaryocyte and platelet microparticles achieves transcellular signaling |
| Q40809666 | Activated factor VII-antithrombin complex predicts mortality in patients with stable coronary artery disease: a cohort study. |
| Q39337755 | Activated platelet chemiluminescence and presence of CD45+ platelets in patients with acute myocardial infarction. |
| Q50706406 | Activated platelet-derived microparticles in thalassaemia. |
| Q26998742 | Activation of blood coagulation in cancer: implications for tumour progression |
| Q40350469 | Activation of caspase-3-dependent and -independent pathways during 7-ketocholesterol- and 7beta-hydroxycholesterol-induced cell death: a morphological and biochemical study |
| Q85074568 | Active tissue factor and activated factor XI in circulating blood of patients with systolic heart failure due to ischemic cardiomyopathy |
| Q34002877 | Adipocytokines in atherothrombosis: focus on platelets and vascular smooth muscle cells |
| Q35204306 | Administered circulating microparticles derived from lung cancer patients markedly improved angiogenesis, blood flow and ischemic recovery in rat critical limb ischemia |
| Q79086329 | Aggregates of endothelial microparticles and platelets circulate in peripheral blood. Variations during stable coronary disease and acute myocardial infarction |
| Q43156601 | Alteration of circulatory platelet microparticles and endothelial microparticles in patients with chronic kidney disease |
| Q36035053 | Alteration of marrow cell gene expression, protein production, and engraftment into lung by lung-derived microvesicles: a novel mechanism for phenotype modulation. |
| Q28185844 | Alternatively spliced human tissue factor: a circulating, soluble, thrombogenic protein |
| Q36956400 | Alveolar cell apoptosis is dependent on p38 MAP kinase-mediated activation of xanthine oxidoreductase in ventilator-induced lung injury |
| Q52927674 | Antioxidative treatment inhibits the release of thrombogenic tissue factor from irradiation- and cytokine-induced endothelial cells. |
| Q33959479 | Apoptosis in the vasculature: mechanisms and functional importance |
| Q48280242 | Applicability of extracellular vesicles in clinical studies. |
| Q37510353 | Are endothelial microparticles potential markers of vascular dysfunction in the antiphospholipid syndrome? |
| Q44973654 | Assessment of the coagulation profile in hemato-oncological patients receiving ATG-based conditioning treatment for allogeneic stem cell transplantation |
| Q42129359 | Association between vascular access failure and microparticles in hemodialysis patients |
| Q53282840 | Association of endothelial microparticle with NO, eNOS, ET-1, and fractional flow reserve in patients with coronary intermediate lesions. |
| Q42008613 | Autocrine activation of human monocyte/macrophages by monocyte-derived microparticles and modulation by PPARγ ligands |
| Q92853263 | Biology and Role of Extracellular Vesicles (EVs) in the Pathogenesis of Thrombosis |
| Q39381245 | Blood level of CD45+ platelets and development of restenosis after drug-eluting stent implantation in patients with stable coronary artery disease |
| Q40151220 | Blood-borne tissue factor activity predicts major cerebrovascular events in patients undergoing carotid endarterectomy: results from a 1-year follow-up study. |
| Q36257626 | Bubble-Induced Endothelial Microparticles Promote Endothelial Dysfunction |
| Q34284335 | CLEC-2 expression is maintained on activated platelets and on platelet microparticles. |
| Q37507632 | Can we use statins to prevent stroke in Fabry disease? |
| Q36832898 | Cell-derived microparticles and exosomes in neuroinflammatory disorders |
| Q46470673 | Cell-derived microparticles contain caspase 3 in vitro and in vivo |
| Q37295504 | Cell-derived microparticles in atherosclerosis: biomarkers and targets for pharmacological modulation? |
| Q34160603 | Cellular microparticle and thrombogram phenotypes in the Prospective Observational Multicenter Major Trauma Transfusion (PROMMTT) study: correlation with coagulopathy |
| Q34203939 | Cellular phenotype switching and microvesicles |
| Q43964856 | Cellular prion protein is expressed on endothelial cells and is released during apoptosis on membrane microparticles found in human plasma |
| Q44410424 | Characterisation and properties of ectosomes released by human polymorphonuclear neutrophils |
| Q37004064 | Characterizing blood microparticles: technical aspects and challenges. |
| Q40070588 | Chemotherapy-induced thrombin generation via procoagulant endothelial microparticles is independent of tissue factor activity |
| Q98771397 | Childhood Obesity, Endothelial Cell Activation, and Critical Illness |
| Q36055034 | Cholesterol enrichment of human monocyte/macrophages induces surface exposure of phosphatidylserine and the release of biologically-active tissue factor-positive microvesicles. |
| Q43472325 | Circulating CD31+/Annexin V+ microparticles correlate with cardiovascular outcomes |
| Q26749422 | Circulating Endothelial Microparticles: A Key Hallmark of Atherosclerosis Progression |
| Q37188204 | Circulating Extracellular Vesicles Contain miRNAs and are Released as Early Biomarkers for Cardiac Injury. |
| Q35904860 | Circulating Microparticles and Coronary Plaque Components Assessed by Virtual Histology Intravascular Ultrasound of the Target Lesion in Patients with Stable Angina |
| Q35908304 | Circulating annexin V positive microparticles in patients after successful cardiopulmonary resuscitation |
| Q38944216 | Circulating cell-derived microparticles as biomarkers in cardiovascular disease |
| Q37539000 | Circulating contact-pathway-activating microparticles together with factors IXa and XIa induce spontaneous clotting in plasma of hematology and cardiologic patients |
| Q34504397 | Circulating endothelial cells are an early predictor in renal cell carcinoma for tumor response to sunitinib |
| Q36447619 | Circulating endothelial cells, endothelial progenitor cells, and endothelial microparticles in cancer |
| Q37293820 | Circulating endothelial cells, microparticles and progenitors: key players towards the definition of vascular competence |
| Q53497260 | Circulating endothelial microparticles as a marker of cerebrovascular disease. |
| Q35212590 | Circulating endothelial microparticles as a measure of early lung destruction in cigarette smokers |
| Q48536084 | Circulating endothelial microparticles in acute ischemic stroke: a link to severity, lesion volume and outcome |
| Q84293220 | Circulating endothelial microparticles in children with Henoch-Schönlein purpura; preliminary results |
| Q33996570 | Circulating endothelial microparticles in diabetes mellitus |
| Q33908558 | Circulating endothelial-derived activated microparticle: a useful biomarker for predicting one-year mortality in patients with advanced non-small cell lung cancer |
| Q42745980 | Circulating endothelial-derived apoptotic microparticles in the patients with ischemic symptomatic chronic heart failure: relevance of pro-inflammatory activation and outcomes. |
| Q38836585 | Circulating extracellular vesicles: Their role in tissue repair and regeneration |
| Q41712425 | Circulating levels and characterization of microparticles in patients with different degrees of glucose tolerance |
| Q98197762 | Circulating microparticle concentrations across acute and chronic cardiovascular disease conditions |
| Q51761177 | Circulating microparticles and endothelial progenitor cells in atherosclerosis: pharmacological effects of irbesartan. |
| Q50591830 | Circulating microparticles and procoagulant activity in elderly patients. |
| Q45888495 | Circulating microparticles are elevated in haemophiliacs and non-haemophilic individuals aged <18 years. |
| Q43608491 | Circulating microparticles are prognostic biomarkers in advanced non-small cell lung cancer patients. |
| Q35014306 | Circulating microparticles carry oxidation-specific epitopes and are recognized by natural IgM antibodies |
| Q37448030 | Circulating microparticles enhanced rat vascular wall remodeling following endothelial denudation |
| Q31137300 | Circulating microparticles from Crohn's disease patients cause endothelial and vascular dysfunctions |
| Q40667685 | Circulating microparticles from diabetic rats impair endothelial function and regulate endothelial protein expression. |
| Q46344026 | Circulating platelet and erythrocyte microparticles in young children and adolescents with sickle cell disease: Relation to cardiovascular complications. |
| Q28169115 | Circulating procoagulant microparticles and soluble GPV in myocardial infarction treated by primary percutaneous transluminal coronary angioplasty. A possible role for GPIIb-IIIa antagonists |
| Q53292843 | Circulating procoagulant microparticles in cancer patients. |
| Q36262859 | Circulating thrombotic and haemostatic components in patients with coronary artery disease |
| Q37610439 | Clinical CVVH model removes endothelium-derived microparticles from circulation |
| Q36517055 | Clinical and therapeutical implications of EPC biology in atherosclerosis |
| Q33242082 | Clinical methods for the evaluation of endothelial function-- a focus on resistance arteries |
| Q37782534 | Clinical relevance of microparticles from platelets and megakaryocytes |
| Q44941576 | Collagen-induced generation of platelet-derived microparticles in whole blood is dependent on ADP released from red blood cells and calcium ions. |
| Q33425421 | Complement Interactions with Blood Cells, Endothelial Cells and Microvesicles in Thrombotic and Inflammatory Conditions |
| Q54940870 | Coronary Serum Exosomes Derived from Patients with Myocardial Ischemia Regulate Angiogenesis through the miR-939-mediated Nitric Oxide Signaling Pathway. |
| Q35934133 | Counting the cost: markers of endothelial damage in hematopoietic stem cell transplantation |
| Q87442820 | Crocin, a dietary additive protects platelets from oxidative stress-induced apoptosis and inhibits platelet aggregation |
| Q40474039 | Cutting-edge analysis of extracellular microparticles using ImageStream(X) imaging flow cytometry. |
| Q48855551 | Decreased circulating endothelial progenitor cell levels and function in essential hypertensive patients with electrocardiographic left ventricular hypertrophy |
| Q33375739 | Diagnosis and treatment of transplantation-associated thrombotic microangiopathy: real progress or are we still waiting? |
| Q42486870 | Disrupted Endothelial Cell Layer and Exposed Extracellular Matrix Proteins Promote Capture of Late Outgrowth Endothelial Progenitor Cells |
| Q47769927 | Diurnal variation of circulating microvesicles is associated with the severity of obstructive sleep apnoea |
| Q43580915 | Do atrial differences in endothelial damage, leukocyte and platelet activation, or tissue factor activity contribute to chamber-specific thrombogenic status in patients with atrial fibrillation? |
| Q37732309 | Do platelet-derived microparticles play a role in depression, inflammation, and acute coronary syndrome? |
| Q58597959 | Dysfunctional endothelial-derived microparticles promote inflammatory macrophage formation via NF-кB and IL-1β signal pathways |
| Q43524827 | Early heparin administration attenuates tissue factor-mediated thrombin generation during simulated cardiopulmonary bypass |
| Q41765654 | Effect of abciximab on the levels of circulating microparticles in patients with acute myocardial infarction treated by primary angioplasty |
| Q94475026 | Effects and Mechanisms of Vitamin C Post-Conditioning on Platelet Activation after Hypoxia/Reoxygenation |
| Q91789997 | Effects of HIV-1 gp120 and TAT-derived microvesicles on endothelial cell function |
| Q36719448 | Effects of a nutraceutical combination on lipids, inflammation and endothelial integrity in patients with subclinical inflammation: a randomized clinical trial |
| Q34159834 | Effects of disturbed flow on vascular endothelium: pathophysiological basis and clinical perspectives |
| Q53054796 | Effects of ezetimibe on endothelial progenitor cells and microparticles in high-risk patients. |
| Q33813731 | Effects of immunoadsorption on endothelial function, circulating endothelial progenitor cells and circulating microparticles in patients with inflammatory dilated cardiomyopathy |
| Q51738736 | Effects of transplanted circulating endothelial progenitor cells and platelet microparticles in atherosclerosis development. |
| Q88881058 | Elevated circulating endothelial cell-derived microparticle levels in patients with liver cirrhosis: a preliminary report |
| Q57305797 | Elevated levels of interleukin-1?-converting enzyme and caspase-cleaved cytokeratin-18 in acute myocardial infarction |
| Q24816944 | Elevated levels of procoagulant microparticles in a patient with myocardial infarction, antiphospholipid antibodies and multifocal cardiac thrombosis |
| Q34927281 | Elevated levels of procoagulant plasma microvesicles in dialysis patients. |
| Q45117210 | Elevated levels of thrombin-generating microparticles in stored red blood cells |
| Q79102771 | Elevated plasma endothelial microparticles in preeclampsia |
| Q88692135 | Elevated plasma levels of procoagulant microparticles are a novel risk factor for thrombosis in patients with myeloproliferative neoplasms |
| Q35054048 | Elevated procoagulant endothelial and tissue factor expressing microparticles in women with recurrent pregnancy loss |
| Q37246729 | Elevated procoagulant microparticles expressing endothelial and platelet markers in essential thrombocythemia |
| Q27016553 | Emerging roles for platelets as immune and inflammatory cells |
| Q33639065 | Endothelial Extracellular Vesicles-Promises and Challenges |
| Q28071774 | Endothelial Microparticles Act as Novel Diagnostic and Therapeutic Biomarkers of Diabetes and Its Complications: A Literature Review |
| Q37760426 | Endothelial activation and circulating markers of endothelial activation in kidney disease |
| Q38953820 | Endothelial and cancer cells interact with mesenchymal stem cells via both microparticles and secreted factors |
| Q40538261 | Endothelial and platelet microparticles in vasculitis of the young. |
| Q90655353 | Endothelial cell apoptosis and the role of endothelial cell-derived extracellular vesicles in the progression of atherosclerosis |
| Q48478550 | Endothelial cell apoptosis in obstructive sleep apnea: a link to endothelial dysfunction |
| Q35489022 | Endothelial cell microparticles act as centers of matrix metalloproteinsase-2 (MMP-2) activation and vascular matrix remodeling |
| Q40646486 | Endothelial cells release phenotypically and quantitatively distinct microparticles in activation and apoptosis |
| Q36891589 | Endothelial dysfunction caused by circulating microparticles from patients with metabolic syndrome. |
| Q42342948 | Endothelial dysfunction in cardiovascular disease and Flammer syndrome-similarities and differences |
| Q57612996 | Endothelial dysfunction in systemic lupus patients with low disease activity: evaluation by quantification and characterization of circulating endothelial microparticles, role of anti-endothelial cell antibodies |
| Q83288068 | Endothelial dysfunction in type 2 diabetes |
| Q48118627 | Endothelial microparticle levels are similar in acute ischemic stroke and stroke mimics due to activation and not apoptosis/necrosis |
| Q36192477 | Endothelial microparticles (EMP) as vascular disease markers. |
| Q39186270 | Endothelial microparticles act as novel diagnostic and therapeutic biomarkers of circulatory hypoxia-related diseases: a literature review |
| Q37319478 | Endothelial microparticles in diseases |
| Q82668100 | Endothelial microparticles: a universal marker of vascular health? |
| Q38001993 | Endothelial microparticles: missing link in endothelial dysfunction? |
| Q35624092 | Endothelial microparticles: sophisticated vesicles modulating vascular function |
| Q37679623 | Endothelial progenitor cells and endothelial vesicles - what is the significance for patients with chronic kidney disease? |
| Q36799382 | Endothelial progenitor cells in health and atherosclerotic disease |
| Q88331120 | Endothelial vascular markers in coronary surgery |
| Q44693041 | Eptifibatide-induced thrombocytopenia and circulating procoagulant platelet-derived microparticles in a patient with acute coronary syndrome |
| Q36476672 | Evaluation of Endothelial and Platelet Derived Microparticles in Patients with Acute Coronary Syndrome. |
| Q44284893 | Evaluation of microparticles in whole blood by multicolour flow cytometry assay |
| Q38994668 | Exosomes and Cardiovascular Protection. |
| Q36868727 | Expression, activation, and function of integrin alphaMbeta2 (Mac-1) on neutrophil-derived microparticles |
| Q58719835 | Extracellular Vesicles as Biomarkers in Cardiovascular Disease; Chances and Risks |
| Q37801877 | Extracellular heat shock proteins, cellular export vesicles, and the Stress Observation System: a form of communication during injury, infection, and cell damage. It is never known how far a controversial finding will go! Dedicated to Ferruccio Rito |
| Q39115035 | Extracellular vesicles in coronary artery disease. |
| Q46817747 | Fetal corticotrophin-releasing hormone mRNA, but not phosphatidylserine-exposing microparticles, in maternal plasma are associated with factor VII activity in pre-eclampsia |
| Q53036476 | Flow cytometric assessment of endothelial and platelet microparticles in preeclampsia and their relation to disease severity and Doppler parameters. |
| Q44139130 | Flow cytometric findings in platelets of patients following allogeneic hematopoietic stem cell transplantation |
| Q33424474 | Functional SNPs in HSPA1A gene predict risk of coronary heart disease |
| Q39099983 | Glucose and angiotensin II-derived endothelial extracellular vesicles regulate endothelial dysfunction via ERK1/2 activation |
| Q73502484 | High levels of circulating endothelial microparticles in patients with acute coronary syndromes |
| Q42701294 | High-Dose Vitamin C Injection to Cancer Patients May Promote Thrombosis Through Procoagulant Activation of Erythrocytes |
| Q37718866 | High-density lipoproteins, platelets and the pathogenesis of atherosclerosis |
| Q50217083 | How to quantify microparticles in RBCs? A validated flow cytometry method allows the detection of an increase in microparticles during storage. |
| Q34291730 | Human cell-derived microparticles promote thrombus formation in vivo in a tissue factor-dependent manner. |
| Q36003122 | Hyperphosphatemia, Phosphoprotein Phosphatases, and Microparticle Release in Vascular Endothelial Cells. |
| Q52028856 | Identification and characterization of murine alternatively spliced tissue factor. |
| Q47859486 | Immunoaffinity based methods are superior to kits for purification of prostate derived extracellular vesicles from plasma samples. |
| Q55035469 | Impact of Intracoronary Adenosine on Myonecrosis in Patients with Unstable Angina Pectoris Undergoing Percutaneous Coronary Intervention. |
| Q37316399 | Impact of endothelial microparticles on coagulation, inflammation, and angiogenesis in age-related vascular diseases |
| Q38289218 | Impact of platelet phenotype on myocardial infarction. |
| Q36399434 | Impaired clearance of apoptotic cells promotes synergy between atherogenesis and autoimmune disease |
| Q34849981 | Increased circulating endothelial apoptotic microparticle to endothelial progenitor cell ratio is associated with subsequent decline in glomerular filtration rate in hypertensive patients |
| Q43252713 | Increased levels of tissue factor activity and procoagulant phospholipids during treatment of children with acute lymphoblastic leukaemia |
| Q35582078 | Increased serum concentrations of soluble CD95/Fas and caspase 1/ICE in patients with acute angina |
| Q44694358 | Indicators of lifetime endogenous estrogen exposure and risk of venous thromboembolism |
| Q26823258 | Inflammation and haemostasis |
| Q37307660 | Inflammation and plaque vulnerability |
| Q90481598 | Inflammatory extracellular vesicles prompt heart dysfunction via TRL4-dependent NF-κB activation |
| Q38355385 | Inflammatory markers in ST-elevation acute myocardial infarction |
| Q40061733 | Influence of Diabetes on Circulating Apoptotic Microparticles in Patients with Chronic Hepatitis C. |
| Q35060112 | Interferon-beta1a reduces plasma CD31+ endothelial microparticles (CD31+EMP) in multiple sclerosis |
| Q37240164 | Internalization of tissue factor by platelets. |
| Q41632953 | Intracoronary adenosine to prevent myonecrosis in patients with stable angina undergoing percutaneous interventions: a double-blinded randomized controlled trial |
| Q58230148 | Intracoronary microparticles and microvascular obstruction in patients with ST elevation myocardial infarction undergoing primary percutaneous intervention |
| Q35631232 | Isolation and phenotypic characteristics of microparticles in acute respiratory distress syndrome |
| Q37208677 | Levels of circulating microparticles in lung cancer patients and possible prognostic value. |
| Q38627278 | Lipoproteins as modulators of atherothrombosis: From endothelial function to primary and secondary coagulation |
| Q37486626 | Long-term secondary prevention programs after cardiac rehabilitation for the reduction of future cardiovascular events: focus on regular physical activity |
| Q43067705 | Low dose acetylsalicylic acid and shedding of microparticles in vivo in humans |
| Q40043141 | Lymphocytic microparticles inhibit angiogenesis by stimulating oxidative stress and negatively regulating VEGF-induced pathways |
| Q36892515 | Mammalian plasma membrane proteomics |
| Q39026344 | Markers of endothelial damage in patients with chronic kidney disease on hemodialysis. |
| Q38215838 | Mechanism of antiplatelet action of hypolipidemic, antidiabetic and antihypertensive drugs by PPAR activation: PPAR agonists: new antiplatelet agents. |
| Q35088065 | Mechanisms of plaque vulnerability and rupture |
| Q30485800 | Megakaryocyte-derived microparticles: direct visualization and distinction from platelet-derived microparticles |
| Q34026858 | Membrane vesicles, current state-of-the-art: emerging role of extracellular vesicles |
| Q64076796 | Metabolic signature of extracellular vesicles depends on the cell culture conditions |
| Q35661078 | Methodology for isolation, identification and characterization of microvesicles in peripheral blood |
| Q33857901 | Methods for evaluating endothelial function: a position statement from the European Society of Cardiology Working Group on Peripheral Circulation |
| Q35180264 | MicroRNA-223 delivered by platelet-derived microvesicles promotes lung cancer cell invasion via targeting tumor suppressor EPB41L3. |
| Q38110225 | MicroRNAs as biomarkers for ischemic heart disease |
| Q33399130 | Microparticle generation and leucocyte death in Shiga toxin-mediated HUS. |
| Q33374589 | Microparticle-associated P-selectin reflects platelet activation in preeclampsia |
| Q40260694 | Microparticle-associated tissue factor activity: a link between cancer and thrombosis? |
| Q90686994 | Microparticles and autophagy: a new frontier in the understanding of atherosclerosis in rheumatoid arthritis |
| Q38805409 | Microparticles and cancer thrombosis in animal models. |
| Q36964906 | Microparticles and exosomes: impact on normal and complicated pregnancy |
| Q38334501 | Microparticles as potential biomarkers of cardiovascular disease |
| Q43265582 | Microparticles in deep venous thrombosis, antiphospholipid syndrome and Factor V Leiden. |
| Q38118341 | Microparticles in health and disease. |
| Q35131040 | Microparticles in hemostasis and thrombosis. |
| Q39603636 | Microparticles in tumor progression. |
| Q46541119 | Microparticles released by human neutrophils adhere to erythrocytes in the presence of complement |
| Q37769584 | Microparticles--messengers of biological information |
| Q41688602 | Microvesicles Derived from Indoxyl Sulfate Treated Endothelial Cells Induce Endothelial Progenitor Cells Dysfunction. |
| Q49807920 | Microvesicles as Emerging Biomarkers and Therapeutic Targets in Cardiometabolic Diseases |
| Q34961040 | Microvesicles at the crossroads between infection and cardiovascular diseases |
| Q49741768 | Microvesicles in Atherosclerosis and Angiogenesis: From Bench to Bedside and Reverse |
| Q37981578 | Microvesicles in health and disease. |
| Q21129259 | Microvesicles: novel biomarkers for neurological disorders |
| Q38077234 | Microvesiculation and disease. |
| Q48220941 | Mitochondria-targeted esculetin inhibits PAI-1 levels by modulating STAT3 activation and miR-19b via SIRT3: Role in acute coronary artery syndrome. |
| Q64237035 | Molecular Mechanisms Underpinning Microparticle-Mediated Cellular Injury in Cardiovascular Complications Associated with Diabetes |
| Q40659069 | Monocyte exosomes induce adhesion molecules and cytokines via activation of NF-κB in endothelial cells |
| Q44087426 | Monocyte-derived macrophage microparticles impart tissue factor activity to biomaterial surfaces |
| Q43064579 | NADPH oxidase in vascular injury: a new insight about its regulation and role in T cells |
| Q35988834 | Natural antibodies and the autoimmunity of atherosclerosis. |
| Q37589724 | Neutrophil-derived microparticles are released into the coronary circulation following percutaneous coronary intervention in acute coronary syndrome patients |
| Q35088528 | New understanding, diagnosis, and prognosis of atherothrombosis and the role of imaging |
| Q36965838 | Non-traditional biomarkers of atherosclerosis in stable and unstable coronary artery disease, do they differ? |
| Q39201920 | Nonclinical safety biomarkers of drug-induced vascular injury: current status and blueprint for the future |
| Q26865593 | Noncoding RNAs regulate NF-κB signaling to modulate blood vessel inflammation |
| Q37842018 | Novel endothelial biomarkers: implications for periodontal disease and CVD. |
| Q53063504 | Oat-enriched diet reduces inflammatory status assessed by circulating cell-derived microparticle concentrations in type 2 diabetes. |
| Q27023547 | On the origin of microparticles: From "platelet dust" to mediators of intercellular communication |
| Q35203028 | Oxidation-sensitive mechanisms, vascular apoptosis and atherosclerosis |
| Q35151273 | Pathology of the thin-cap fibroatheroma: a type of vulnerable plaque |
| Q91979008 | Pathophysiology 1. Mechanisms of Thrombosis in Cancer Patients |
| Q35585929 | Pathophysiology of plaque rupture and the concept of plaque stabilization |
| Q36263844 | Peri-procedural myocardial injury: 2005 update |
| Q45324894 | Persistence of circulating endothelial microparticles in COPD despite smoking cessation. |
| Q37267758 | Personalized cytomic assessment of vascular health: Evaluation of the vascular health profile in diabetes mellitus |
| Q36965142 | Phosphate Toxicity in CKD: The Killer among Us |
| Q35845083 | Phospholipid Binding Protein C Inhibitor (PCI) Is Present on Microparticles Generated In Vitro and In Vivo. |
| Q51047838 | PlA2 Polymorphism in Glycoprotein IIb/IIIa Modulates the Morphology and Nanomechanics of Platelets. |
| Q42563535 | Plasma TF activity predicts cardiovascular mortality in patients with acute myocardial infarction |
| Q36759589 | Plasma microparticles and vascular disorders |
| Q33765406 | Plasma tissue factor may be predictive of venous thromboembolism in pancreatic cancer |
| Q89980169 | Platelet Inhibition, Endothelial Function, and Clinical Outcome in Patients Presenting With ST-Segment-Elevation Myocardial Infarction Randomized to Ticagrelor Versus Prasugrel Maintenance Therapy: Long-Term Follow-Up of the REDUCE-MVI Trial |
| Q36958267 | Platelet microparticle number is associated with the extent of myocardial damage in acute myocardial infarction |
| Q38813483 | Platelet proteomics applied to the search for novel antiplatelet therapeutic targets |
| Q63488621 | Platelet-derived microparticle count and surface molecule expression differ between subjects with and without type 2 diabetes, independently of obesity status |
| Q46670831 | Platelet-derived microparticle levels are significantly elevated in patients treated by elective stenting compared to subjects with diagnostic catheterization alone |
| Q40204179 | Platelet-derived microvesicles induce differential gene expression in monocytic cells: a DNA microarray study |
| Q41166174 | Platelets microparticles as a link between micro- and macro-angiopathy in young patients with type 1 diabetes |
| Q44904205 | Polymorphisms in the 5'-UTR of the tissue factor gene are associated with altered expression in human endothelial cells |
| Q37549027 | Premature vascular damage in systemic lupus erythematosus: an imbalance of damage and repair? |
| Q35578042 | Pro-coagulant state resulting from high levels of soluble P-selectin in blood |
| Q37695163 | Procoagulant activity of circulating microparticles is associated with the presence of moderate calcified plaque burden detected by multislice computed tomography |
| Q35158964 | Procoagulant, tissue factor-bearing microparticles in bronchoalveolar lavage of interstitial lung disease patients: an observational study |
| Q36717080 | Protease-activated receptor (PAR) 1 and PAR4 differentially regulate factor V expression from human platelets |
| Q44518956 | Protective effects of vitamin C on endothelium damage and platelet activation during myocardial infarction in patients with sustained generation of circulating microparticles |
| Q28475779 | Proteins involved in platelet signaling are differentially regulated in acute coronary syndrome: a proteomic study |
| Q33225051 | Proteome of endothelial cell-derived procoagulant microparticles |
| Q53474325 | Proteomic analysis of secretory proteins and vesicles in vascular research. |
| Q38106664 | Proteomics of plaques and novel sources of potential biomarkers for atherosclerosis |
| Q28220222 | Prothrombotic markers and early spontaneous recanalization in ST-segment elevation myocardial infarction |
| Q45723763 | Red cell and platelet-derived microparticles are increased in G6PD-deficient subjects |
| Q39882109 | Regulation of cardiomyocyte full-length tissue factor expression and microparticle release under inflammatory conditions in vitro. |
| Q24795283 | Release of annexin V-binding membrane microparticles from cultured human umbilical vein endothelial cells after treatment with camptothecin |
| Q41976719 | Retinal endothelial cell apoptosis stimulates recruitment of endothelial progenitor cells |
| Q38117725 | Revisited role of microparticles in arterial and venous thrombosis. |
| Q53853760 | Role of coronary risk factors in blood thrombogenicity and acute coronary syndromes |
| Q37138036 | Role of microparticles in atherothrombosis |
| Q38811610 | Role of red blood cells in haemostasis and thrombosis |
| Q38034092 | Role of tissue factor in atherothrombosis |
| Q62606141 | Rôle des microparticules cellulaires à l’interface des réponses prothrombotiques et inflammatoires |
| Q37141019 | Serum extracellular vesicle protein levels are associated with acute coronary syndrome |
| Q33397541 | Shiga toxin pathogenesis: kidney complications and renal failure |
| Q35916102 | Signaling pathways involved in OxPAPC-induced pulmonary endothelial barrier protection. |
| Q37996577 | Sources of tissue factor that contribute to thrombosis after rupture of an atherosclerotic plaque |
| Q43658449 | Suppression of endothelial cell apoptosis by high density lipoproteins (HDL) and HDL-associated lysosphingolipids |
| Q33659103 | Suppression of inflammation reduces endothelial microparticles in active systemic lupus erythematosus |
| Q52803280 | The Effect of a Simulated Commercial Flight Environment with Hypoxia and Low Humidity on Clotting, Platelet, and Endothelial Function in Participants with Type 2 Diabetes - A Cross-over Study. |
| Q35821321 | The Interface between Inflammation and Coagulation in Cardiovascular Disease |
| Q57066613 | The Main Determinants of Diabetes Mellitus Vascular Complications: Endothelial Dysfunction and Platelet Hyperaggregation |
| Q38897750 | The Pathogenetic Role of Apoptosis in Hypercoagulable States |
| Q37898220 | The assessment of vascular function during dietary intervention trials in human subjects |
| Q50979016 | The association between endothelial microparticles and inflammation in patients with systemic sclerosis and Raynaud's phenomenon as detected by functional imaging. |
| Q53338269 | The composition and daily variation of microparticles in whole blood in stable coronary artery disease. |
| Q38624868 | The diagnostic and prognostic potential of plasma extracellular vesicles for cardiovascular disease |
| Q38069578 | The emerging role of neutrophils in thrombosis-the journey of TF through NETs |
| Q38212058 | The functional role of platelets in the regulation of angiogenesis |
| Q35566170 | The impact of heparin compounds on cellular inflammatory responses: a construct for future investigation and pharmaceutical development |
| Q36892494 | The impact of insulin resistance on endothelial function, progenitor cells and repair |
| Q36887036 | The interface of inflammation and subclinical atherosclerosis in granulomatosis with polyangiitis (Wegener's): a preliminary study |
| Q35169351 | The interplay of inflammation and cardiovascular disease in systemic lupus erythematosus |
| Q33916623 | The involvement of circulating microparticles in inflammation, coagulation and cardiovascular diseases |
| Q37808230 | The multivalent activity of the tissue factor-thrombin pathway in thrombotic and non-thrombotic disorders as a target for therapeutic intervention |
| Q36647084 | The origin of circulating CD36 in type 2 diabetes. |
| Q39629646 | The presence of apoptotic bone marrow cells impairs the efficacy of cardiac cell therapy |
| Q27003277 | The prothrombotic tendency in metabolic syndrome: focus on the potential mechanisms involved in impaired haemostasis and fibrinolytic balance |
| Q38638694 | The role of microparticles in inflammation and transfusion: A concise review |
| Q27490448 | The role of saliva in tick feeding |
| Q33385836 | Thrombocytopenia and hemostatic disorders in chronic graft versus host disease |
| Q89173387 | Thromboelastography Parameter Predicts Outcome After Subarachnoid Hemorrhage: An Exploratory Analysis |
| Q28195719 | Thrombophilia: implications for pregnancy outcome |
| Q35098992 | Thrombotic microangiopathy in haematopoietic cell transplantation: an update |
| Q33383355 | Thrombotic microangiopathy in haematopoietic stem cell transplantation: diagnosis and treatment |
| Q51124341 | Time courses and value of circulating microparticles in patients with operable stage non-small cell lung cancer undergoing surgical intervention. |
| Q37798969 | Tissue factor in cardiovascular disease pathophysiology and pharmacological intervention |
| Q40942192 | Tissue factor is induced by interleukin-33 in human endothelial cells: a new link between coagulation and inflammation |
| Q38079283 | Tissue factor non-coagulant signaling - molecular mechanisms and biological consequences with a focus on cell migration and apoptosis. |
| Q40293418 | Tissue factor serum levels and the risk of future coronary artery disease in apparently healthy men and women: the EPIC-Norfolk prospective population study |
| Q37618822 | Tissue factor: beyond coagulation in the cardiovascular system |
| Q35568437 | Transcellular delivery of vesicular SOCS proteins from macrophages to epithelial cells blunts inflammatory signaling |
| Q39200565 | Transfer of the chemokine receptor CCR5 between cells by membrane-derived microparticles: a mechanism for cellular human immunodeficiency virus 1 infection |
| Q38086506 | Tumour necrosis factor in infectious disease. |
| Q51450105 | Understanding disease mechanisms at the nanoscale: endothelial apoptosis and microparticles in COPD. |
| Q46266839 | Unfavorable hip stress distribution after Legg-Calvé-Perthes syndrome: a 25-year follow-up of 135 hips |
| Q35868133 | Vascular repair by circulating endothelial progenitor cells: the missing link in atherosclerosis? |
| Q51050982 | Vbeta-restricted T cell adherence to endothelial cells: a mechanism for superantigen-dependent vascular injury. |
| Q52918359 | Viral myocarditis and coagulopathy: increased tissue factor expression and plasma thrombogenicity. |
| Q41692281 | Young women with polycystic ovary syndrome have raised levels of circulating annexin V-positive platelet microparticles |
| Q80088629 | [Markers of thrombotic disease: procoagulant microparticles] |
| Q38383813 | miR-483 Targeting of CTGF Suppresses Endothelial-to-Mesenchymal Transition: Therapeutic Implications in Kawasaki Disease. |
| Q61651374 | von Willebrand Factor Inhibition Improves Endothelial Function in Patients with Stable Angina |
Search more.